Drugs / OMTX705
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07377045 | Oct 2025 → Mar 2029 expected | pancreatic ductal adenocarcinoma | Oncomatryx Biopharma S.L. | Recruiting | No outcome recorded |
| Phase 1 | NCT05547321 | Oct 2022 → Dec 2027 expected | — | Oncomatryx Biopharma S.L. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-08-31 | InxMed (Shanghai) Co., Ltd. | Regulatory 应世生物全球首创ADC药物获中国临床试验许可 inxmed.com ↗
公司正在开发的全球首创抗体偶联毒素（ADC）药物OMTX705日前已经获得中国国家药品监督管理局（China National Medical Products Administration, NMPA）颁发的临床研究批件。 |
| 2022-05-31 | Oncomatryx Biopharma S.L. | Regulatory Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors oncomatryx.com ↗
Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-06 | Oncomatryx Biopharma S.L. | Oncomatryx Convenes Its Scientific Advisory Board to Review OMTX705 and Its Next-Generation ADC Pipeline oncomatryx.com ↗ |
| 2026-07-27 | Oncomatryx Biopharma S.L. | Oncomatryx’s OMTX705 Selected for New Combination Research Collaboration Between InxMed and HanchorBio oncomatryx.com ↗ |
| 2025-01-15 | Oncomatryx Biopharma S.L. | ONCOMATRYX raises €25 Million to foster OMTX705 Clinical Trials oncomatryx.com ↗ |
| 2023-08-31 | InxMed (Shanghai) Co., Ltd. | 应世生物全球首创ADC药物获中国临床试验许可 inxmed.com ↗ |
| 2022-05-31 | Oncomatryx Biopharma S.L. | Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors oncomatryx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMTX705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05547321 ↗ |
| Modality | Other / unclassified | “OMTX705, an Anti-fibroblast Activation Protein Antibody-drug Conjugate” NCT05547321 ↗ |
| Route | Intravenous | “OMTX705 administered IV at 2.0, 4.0 or 7.5 mg/kg on days 1 and 8 every 21-days cycle” NCT07377045 ↗ |